5
Funding Rounds
$134.1m
Money raised
Verge Genomics is a company focused on the discovery and development of drugs for the treatment of neurodegenerative diseases with the use of machine learning and computational genomics.
Industries:
Key people:
- Jason Chen *****@vergegenomics.com
- Alice Zhang *****@vergegenomics.com
6
Funding Rounds
$116.0m
Money raised
Axial Therapeutics is a biopharmaceutical company targeting neurological disorders such as Parkinson's and Autism via gut health.
Industries:
Key people:
- Michelle Dipp linkedin
- David H Donabedian *****@axialtx.com
- Jeffrey E. Young linkedin
1
Funding Rounds
$250.0k
Money raised
Convalesce is a company developing a stem cell based therapy for neurological conditions that leads to degeneration of neurons, like Parkinson's.
Industries:
Location:
Key people:
- Amrutraj Zade ********@convalesce.co
- Subhadeep Das *********@convalesce.co
3
Funding Rounds
$224.0m
Money raised
Aspen Neuroscience develops autologous iPSC-derived cell replacement therapies for Parkinson’s disease and other CNS disorders.
Industries:
Location:
Key people:
2
Funding Rounds
$146.0m
Money raised
Muna develops transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases
Industries:
Location:
2
Funding Rounds
$48.0m
Money raised
Skyhawk Therapeutics is a RNA-correcting Small Molecules founded in 2016 by Bill Haney.
Industries:
Location:
Key people:
- Bill Haney ****@skyhawktx.com
- Kathleen McCarthy ********.********@skyhawktx.com
2
Funding Rounds
$25.0m
Money raised
A biopharmaceutical company that develops therapies to treat Autism, neurological and other disorders
1
Funding Rounds
$6.1m
Money raised
OccamzRazor is an artificial Intelligence company founded in 2015 by Katharina Sophia Volz.
3
Funding Rounds
$33.6m
Money raised
Amyl Therapeutics unique technology offers a curative solution for all forms of amyloid mediated diseases
1
Funding Rounds
$10.5m
Money raised
Novel positive allosteric modulators of the metabotropic glutamate receptor subtype 4
Industries:
Location:
1
Funding Rounds
$500.0k
Money raised
MentiNova's primary strategy is to use L-DOPA, the drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson's disease.
Industries:
Location:
1
Funding Rounds
$41.0m
Money raised
Prexton Therapeutics has the mission to develop innovative drugs to improve the quality of life of people who suffer from Parkinson's disease and other brain disorders.